Dear colleagues and friends,

We are all working together - at GORTEC, Unicancer, GETTEC, GERCOR and now REFCOR - to develop a truly remarkable shared momentum to support clinical research and optimize the treatment of head and neck cancers. Our clinical trials stand out within the global panorama in terms of both number and quality. A significant proportion of our research concerns trials without links to the pharmaceutical industry (Cisfrad, Saltorl, Santal, etc.) and we are also at the forefront when it comes to asking major questions - via the TPextreme trial, for example - and incorporating the latest developments in the field of immunotherapy (REACH, PembroRad, TopNivo, Nivo post-op, Rewrite, Frail-immune etc.).

We owe our success to the invaluable contributions made by each and every one of you and by each investigator site, and also to the support and motivation of our operational teams, to whom I wish to extend my warmest thanks.